Digital Medicine 2.0: The future is in policymaking, paying and protecting

Carlsbad, CA (November 2, 2017) – An exclusive report produced by EBD Group and authored by Forbes contributor Nicole Fisher, covering trends in digital medicine policy, financing, privacy, and partnering, was released today. With perspectives from over seventeen thought leaders in the digital health space representing pharma, tech, regulatory agencies, and investors, this report, Digital Medicine 2.0, builds on the first edition, published in August 2016.

Download Digital Medicine 2.0: The future is in policymaking, paying and protecting here.

The report is presented with support from Demy-Colton, Digital Therapeutics Alliance, Evidation Health, Hogan Lovells, Rock Health and StartUp Health. Key themes include:

  • Further defining digital medicine
  • How partnerships are making the advancement of digital medicine possible
  • Investment trends and funding the future of medicine
  • The shifting regulatory environment and its impact
  • The need for data security and how we can achieve this

The impact of the digital medicine industry is reflected in the comments of contributing thought leaders from top companies and organizations in the field, including Aliki Interactive, Digital Therapeutics Alliance, Evidation Health, Hogan Lovells, Medidata, MDIC, Michael J. Fox Foundation, NostaLab, Omada Health, PULSE@MassChallenge, Qualcomm Life, Roche, Rock Health, Sanofi, Stanford University, StartUp Health, U.S. FDA, and Verily.

Asher Rubin, Global Head of the Life Sciences and Healthcare Industry Team at Hogan Lovells says, “There is more certainty now than there was a year ago about where things fall on the spectrum of tools and toys. We have a better sense of how patients use therapies, how providers use therapies, and how the ecosystem is getting connected.”

“A great digital health partnership depends on complementary skills and a shared goal—often, to find ways to improve patient care by understanding what it is really like to live with a disease,” asserts Heather Bell, Senior VP and Global Head of Digital and Analytics at Sanofi.

“Right now we’re in the fact-finding stage with digital health for Parkinson’s: what can we measure and how may that be useful in understanding and treating this disease,” says Deputy
CEO Sohini Chowdhury of the Michael J. Fox Foundation. “Parkinson’s is a very variable disease, which makes real-time monitoring with digital health tools attractive to researchers and patients.”

The convergence of digital technologies and healthcare opens up valuable opportunities for partnerships that will result in innovative solutions that improve patients’ lives. All stakeholders, from researchers, patients, payers and providers, as well as new entrants in this field, will need to adapt and adopt these new technologies to realize the promise of digital medicine.

Download the Digital Medicine 2.0 Whitepaper.

By | 2017-11-09T13:14:19+00:00 November 2nd, 2017|Press Releases & Statements|